drug
trifarotene
Marketedupdated 3mo agoby Galderma Laboratories LP
Approvedcommunity read0 votes
all catalysts(0)
nothing on the calendar yet
Trials studying trifarotene
- phase3A Study to Compare the Efficacy, Safety and Pharmacokinetics of Trifarotene 50 mcg/g Cream in Chinese Subjects With Acne Vulgaris
- phase1A Study Comparing Trifarotene Cream 0.005% to AKLIEF® CREAM (US REFERENCE LISTED DRUG), AKLIEF™ CREAM (CANADIAN REFERENCE PRODUCT) in the Treatment of Acne Vulgaris
- phase3Study Comparing Trifarotene Cream, 0.005% To AKLIEF ® (Trifarotene 0.005% Cream) In The Treatment Of Acne Vulgaris
- phase4Study of Trifarotene Cream to Assess Risk of a Trophic Acne Scar Formation
- phase4AkLief Evaluation in Acne-induced Post-Inflammatory Hyperpigmentation
- phase1A Study Comparing Trifarotene Cream 0.005% to AKLIEF® Cream in the Treatment of Acne Vulgaris
Patent cliff
source: FDA Orange Bookfirst barrier falls
Jul 19, 2031
~4.9 years out
Earliest of all listed patents + FDA exclusivities. Generic / biosimilar entry typically only becomes possible AFTER both patent and exclusivity barriers expire.
patents (3)
- May 30, 2033formulationUS 9084778
- May 30, 2033formulationUS 9498465
- Jul 19, 2031compositionUS 78077084.9y
News(0)
no news has mentioned this drug yet
Data sources
last refreshed 36m ago
Found something off?
comments(0)
5-min edit window · permanent after that